针对饮酒的HIV/HCV合并感染俄罗斯女性的计算机化减酒干预:随机对照试验研究方案
俄罗斯HIV感染者超百万且女性占三分之一以上,HIV/HCV合并感染女性饮酒影响治疗与预后,但循证减酒干预有限。本试验拟招募200名21-45岁确诊HIV/HCV合并感染且当前饮酒的女性,1:1随机分配至计算机化减酒干预组或标准照护组,以EtG及HIV/HCV疾病进展生物标志物评估9个月随访期内干预效果,采用意向性分析及logistic和线性广义估计方程。
要点
- 针对HIV/HCV合并感染且饮酒的俄罗斯女性,评估计算机化减酒干预效果。
- 主要结局为9个月随访各访视点实验室确认的EtG阴性比例。
- 次要分析评估HIV病毒载量、CD4+水平及FibroScan等疾病进展标志物。
核心结论
- 该试验设计为评估计算机化减酒干预对HIV/HCV合并感染俄罗斯女性减酒及改善HIV/HCV预后的 efficacy 提供方法学框架。
研究设计与样本
- 两臂平行随机对照试验,拟招募200名21-45岁确诊HIV/HCV合并感染且当前饮酒的女性。
- 采用计算机生成分配序列及分配隐藏技术,按1:1比例随机分配至计算机化减酒干预组或标准照护对照组。
- 采用意向性分析、logistic和线性广义估计方程评估干预效果,随访期9个月。
主要发现
- 原文为研究方案,未报告干预效果数据。
关键数值与推荐
- 主要结局为9个月随访期内各研究访视点实验室确认的EtG阴性女性比例。
- 次要结局包括HIV病毒载量、CD4+水平及FibroScan等HIV/HCV疾病进展标志物。
- 干预 efficacy 以新型酒精生物标志物乙基葡萄糖醛酸苷(EtG)及HIV/HCV疾病进展生物标志物评估。
临床怎么用
- 若干预有效,可能成为高效、成本效益好、可扩展并易于整合入俄罗斯临床照护的减酒策略。
局限性
- 原文为研究方案,尚未报告实际干预效果与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Russia has a high prevalence of human immunodeficiency virus (HIV) infections. In 2018, over one million persons were living with HIV (PLWH); over a third were women. A high proportion of HIV-infected women are co-infected with hepatitis C virus (HCV), and many consume alcohol, which adversely affects HIV and HCV treatment and prognosis. Despite the triple epidemics of alcohol use, HIV and HCV, and the need for interventions to reduce alcohol use among HIV/HCV co-infected women, evidence-based alcohol reduction interventions for this vulnerable population are limited. To address this gap, we developed a clinical trial to evaluate the efficacy of a computer-based intervention to reduce alcohol consumption among HIV/HCV co-infected women in clinical care. METHODS: In this two-arm parallel randomized controlled trial, we propose to evaluate the efficacy of a culturally adapted alcohol reduction intervention delivered via a computer for HIV/HCV co-infected Russian women. The study population consists of women 21-45 years old with confirmed HIV/HCV co-infection who currently use alcohol. Intervention efficacy is assessed by a novel alcohol biomarker, ethyl glucuronide (EtG), and biomarkers of HIV and HCV disease progression. Women are randomized to trial conditions in a 1:1 allocation ratio, using a computer-generated algorithm to develop the assignment sequence and concealment of allocation techniques to minimize assignment bias. Women are randomized to either (1) the computer-based alcohol reduction intervention or (2) the standard-of-care control condition. We will use an intent-to-treat analysis and logistic and linear generalized estimating equations to evaluate intervention efficacy, relative to the standard of care, in enhancing the proportion of women with a laboratory-confirmed negative EtG at each research study visit over the 9-month follow-up period. Additional analyses will evaluate intervention effects on HIV (viral load and CD4+ levels) and HCV markers of disease progression (FibroScan). DISCUSSION: The proposed trial design and analysis provides an appropriate conceptual and methodological framework to assess the efficacy of the computer-based intervention. We propose to recruit 200 participants. The intervention, if efficacious, may be an efficient and cost-effective alcohol reduction strategy that is scalable and can be readily disseminated and integrated into clinical care in Russia to reduce women's alcohol consumption and enhance HIV/HCV prognosis. TRIAL REGISTRATION: ClinicalTrials.gov NCT03362476 . Registered on 5 December 2017.
引用
- DiClemente RJ, Brown JL, Capasso A, et al. Computer-based alcohol reduction intervention for alcohol-using HIV/HCV co-infected Russian women in clinical care: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33596972. doi:10.1186/s13063-021-05079-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。